Drug candidate AC102 in the clinical phase Investors in the current financing round with AudioCure Management. From left to right: Philipp Zöller (CEO InfectoPharm), Prof Hans Rommelspacher (founder AudioCure), Dr Reimar Schlingensiepen (CEO AudioCure), Dr...
Berliner Startup AudioCure wird mit dem Innovationspreis Berlin Brandenburg 2024 ausgezeichnet AC102 konnte im Lärmtrauma-Modell das Hörvermögen fast vollständig wiederherstellen Europaweite klinische Studie mit Hörsturzpatienten läuft Christin Galetzka und Dr....
To date, more than 50% of the patients in the study have been enrolled in seven European countries. The study is testing AC102 as a novel, more effective treatment for sudden hearing loss with fewer side effects. Berlin-based start-up AudioCure Pharma has enrolled...
AC102 restores hearing in a preclinical model of sudden hearing loss by protecting inner ear neurons and their neuronal connections A Phase 2 clinical study evaluates the efficacy of AC102 in sudden hearing loss patients A single application of the novel compound...
High-dose glucocorticoid regimes do not improve outcomes compared to standard dose but carry greater risk of side effects Glucocorticoid treatment does not result in complete recovery in 60% of patients New treatment options for sudden hearing loss patients are...
This website uses cookies. By clicking on the “Ok” button, you consent to our use of cookies as described in our Privacy Notice. If you continue to use this site we will assume that you agree with our Privacy Police.OkRead more
